JP2011503212A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011503212A5 JP2011503212A5 JP2010534267A JP2010534267A JP2011503212A5 JP 2011503212 A5 JP2011503212 A5 JP 2011503212A5 JP 2010534267 A JP2010534267 A JP 2010534267A JP 2010534267 A JP2010534267 A JP 2010534267A JP 2011503212 A5 JP2011503212 A5 JP 2011503212A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- tissue
- nitrite
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 28
- 210000001519 tissue Anatomy 0.000 claims 11
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 claims 7
- 230000000302 ischemic effect Effects 0.000 claims 7
- 208000028867 ischemia Diseases 0.000 claims 4
- 206010052428 Wound Diseases 0.000 claims 3
- 208000027418 Wounds and injury Diseases 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 210000004204 blood vessel Anatomy 0.000 claims 3
- 230000001684 chronic effect Effects 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 206010022562 Intermittent claudication Diseases 0.000 claims 2
- 210000002808 connective tissue Anatomy 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 208000021156 intermittent vascular claudication Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 210000003491 skin Anatomy 0.000 claims 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical group [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 230000029663 wound healing Effects 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000010392 Bone Fractures Diseases 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 206010017076 Fracture Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 229910002651 NO3 Inorganic materials 0.000 claims 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 1
- 206010031252 Osteomyelitis Diseases 0.000 claims 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- AZFNGPAYDKGCRB-XCPIVNJJSA-M [(1s,2s)-2-amino-1,2-diphenylethyl]-(4-methylphenyl)sulfonylazanide;chlororuthenium(1+);1-methyl-4-propan-2-ylbenzene Chemical compound [Ru+]Cl.CC(C)C1=CC=C(C)C=C1.C1=CC(C)=CC=C1S(=O)(=O)[N-][C@@H](C=1C=CC=CC=1)[C@@H](N)C1=CC=CC=C1 AZFNGPAYDKGCRB-XCPIVNJJSA-M 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 229910001959 inorganic nitrate Inorganic materials 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 208000023589 ischemic disease Diseases 0.000 claims 1
- 208000030175 lameness Diseases 0.000 claims 1
- 201000002818 limb ischemia Diseases 0.000 claims 1
- 230000036244 malformation Effects 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 210000004165 myocardium Anatomy 0.000 claims 1
- 210000000944 nerve tissue Anatomy 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- RAFRTSDUWORDLA-UHFFFAOYSA-N phenyl 3-chloropropanoate Chemical compound ClCCC(=O)OC1=CC=CC=C1 RAFRTSDUWORDLA-UHFFFAOYSA-N 0.000 claims 1
- 235000010289 potassium nitrite Nutrition 0.000 claims 1
- 239000004304 potassium nitrite Substances 0.000 claims 1
- 230000000284 resting effect Effects 0.000 claims 1
- 210000002027 skeletal muscle Anatomy 0.000 claims 1
- 210000002460 smooth muscle Anatomy 0.000 claims 1
- 235000010288 sodium nitrite Nutrition 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000008736 traumatic injury Effects 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US315007P | 2007-11-15 | 2007-11-15 | |
| US61/003,150 | 2007-11-15 | ||
| PCT/US2008/083830 WO2009065142A2 (en) | 2007-11-15 | 2008-11-17 | Use of nitrite salts in chronic ischemia |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014097072A Division JP5908527B2 (ja) | 2007-11-15 | 2014-05-08 | 慢性虚血における亜硝酸塩の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011503212A JP2011503212A (ja) | 2011-01-27 |
| JP2011503212A5 true JP2011503212A5 (https=) | 2012-02-16 |
| JP5795165B2 JP5795165B2 (ja) | 2015-10-14 |
Family
ID=40639493
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010534267A Active JP5795165B2 (ja) | 2007-11-15 | 2008-11-17 | 慢性虚血における亜硝酸塩の使用 |
| JP2014097072A Expired - Fee Related JP5908527B2 (ja) | 2007-11-15 | 2014-05-08 | 慢性虚血における亜硝酸塩の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014097072A Expired - Fee Related JP5908527B2 (ja) | 2007-11-15 | 2014-05-08 | 慢性虚血における亜硝酸塩の使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US9649334B2 (https=) |
| EP (1) | EP2219657A4 (https=) |
| JP (2) | JP5795165B2 (https=) |
| CN (1) | CN101939014B (https=) |
| AU (1) | AU2008322437B2 (https=) |
| IL (1) | IL205720A (https=) |
| WO (1) | WO2009065142A2 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2219657A4 (en) | 2007-11-15 | 2020-01-08 | Louisiana State University | USE OF NITRITE SALTS IN CHRONIC ISCHEMIA |
| US8568793B2 (en) * | 2009-02-11 | 2013-10-29 | Hope Medical Enterprises, Inc. | Sodium nitrite-containing pharmaceutical compositions |
| US20120237617A1 (en) * | 2009-06-18 | 2012-09-20 | Theravasc Inc. | Use of nitrite salts in treating tissue damage |
| CA2777066C (en) | 2009-10-14 | 2020-02-18 | TheraVasc, LLC | Pharmaceutical formulations of nitrite and uses thereof |
| US20130209584A1 (en) * | 2009-10-14 | 2013-08-15 | Theravasc Inc. | Pharmaceutical formulations of nitrite and uses thereof |
| CA2899602C (en) | 2013-02-20 | 2024-01-30 | Theravasc Inc. | Pharmaceutical uses of inorganic nitrites |
| US10517817B2 (en) | 2013-05-09 | 2019-12-31 | Syk Technologies, Llc | Deep topical systemic nitric oxide therapy apparatus and method |
| WO2017132275A1 (en) | 2016-01-27 | 2017-08-03 | Syk Technologies, Llc | Nitric oxide topical application apparatus and methods |
| TWI698241B (zh) | 2017-09-05 | 2020-07-11 | 國立成功大學 | 用於治療缺血的肝素組合物 |
| WO2020141546A1 (en) | 2019-01-02 | 2020-07-09 | Celagenex Research (India) Pvt. Ltd. | Synergistic nutritional compositions for pain management |
| US12459820B2 (en) | 2020-06-11 | 2025-11-04 | J. W. Randolph Miller | Stabilized and NO2-inhibited nitric oxide generating gels for inhaled nitric oxide therapy |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2914446A (en) | 1958-06-26 | 1959-11-24 | Upjohn Co | Nitrite stabilized ascorbic acid-cyanocobalamin compositions |
| US4650484A (en) | 1983-02-03 | 1987-03-17 | Alza Corporation | Method for treating ischemic conditions |
| IE64726B1 (en) | 1987-11-20 | 1995-08-23 | Elan Corp Plc | Pharmaceutical formulations for preventing drug tolerance |
| US5122384A (en) | 1989-05-05 | 1992-06-16 | Kv Pharmaceutical Company | Oral once-per-day organic nitrate formulation which does not induce tolerance |
| US5278192A (en) | 1992-07-02 | 1994-01-11 | The Research Foundation Of State University Of New York | Method of vasodilator therapy for treating a patient with a condition |
| US6709681B2 (en) | 1995-02-17 | 2004-03-23 | Aberdeen University | Acidified nitrite as an antimicrobial agent |
| US20110196039A9 (en) | 1994-10-05 | 2011-08-11 | Kaesemeyer Wayne H | Controlled release arginine formulations |
| US5648101A (en) * | 1994-11-14 | 1997-07-15 | Tawashi; Rashad | Drug delivery of nitric oxide |
| US5770645A (en) | 1996-08-02 | 1998-06-23 | Duke University Medical Center | Polymers for delivering nitric oxide in vivo |
| US5994444A (en) | 1997-10-16 | 1999-11-30 | Medtronic, Inc. | Polymeric material that releases nitric oxide |
| US7371415B1 (en) | 1998-04-03 | 2008-05-13 | The Daily Wellness Company | Method and composition for improving sexual fitness |
| US7015876B1 (en) | 1998-06-03 | 2006-03-21 | Lear Corporation | Heads-up display with improved contrast |
| US6103275A (en) * | 1998-06-10 | 2000-08-15 | Nitric Oxide Solutions | Systems and methods for topical treatment with nitric oxide |
| WO2000003725A1 (en) | 1998-07-14 | 2000-01-27 | Paracelsian, Inc. | Method for identifying and confirming consistent bio-functionality of natural compositions |
| US6962717B1 (en) | 1999-01-29 | 2005-11-08 | Disphar International B.V. | Pharmaceutical compositions |
| GB9905425D0 (en) | 1999-03-09 | 1999-05-05 | Queen Mary & Westfield College | Pharmaceutical composition |
| US6314956B1 (en) | 1999-09-08 | 2001-11-13 | Duke University | Pulmonary delivery of NO group-containing compound in gas form to treat respiratory, cardiac and blood disorders |
| CN1299690C (zh) * | 2000-07-28 | 2007-02-14 | 生物能量公司 | 用于提高心血管功能的组合物 |
| GB0119011D0 (en) | 2001-08-03 | 2001-09-26 | Univ Aberdeen | Treatment of nail infections |
| EP1492509A1 (en) | 2001-12-18 | 2005-01-05 | ALZA Corporation | Dosage form providing time-varying patterns of drug delivery |
| EP1336602A1 (en) | 2002-02-13 | 2003-08-20 | Giovanni Scaramuzzino | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases |
| CA2379211A1 (fr) | 2002-03-28 | 2003-09-28 | Institut De Cardiologie De Montreal | Utilisation du bleu de methylene pour renverser la reaction hemodynamique exageree induite par la combinaison d'un derive nitre et du sildenafil ou d'une molecule de meme classe (inhibiteur de la phosphodiesterase) |
| ES2294543T3 (es) | 2003-07-09 | 2008-04-01 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Heal | Uso de sales de nitrilo para el tratamiento de afecciones cardiovasculares. |
| JP2007502831A (ja) | 2003-08-20 | 2007-02-15 | ニトロメッド インコーポレーティッド | ニトロソ化およびニトロシル化心血管化合物、組成物、ならびに使用方法 |
| WO2005023189A2 (en) * | 2003-09-03 | 2005-03-17 | Pharmacia Corporation | Method of cox-2 selective inhibitor and nitric oxide-donating agent |
| US7362274B1 (en) * | 2004-07-09 | 2008-04-22 | Huan-Cheng Lien | Coupled feed-in butterfly shaped left/right hand circularly polarized microstrip antenna |
| US20060083824A1 (en) | 2004-10-20 | 2006-04-20 | Pbm Products Llc | Nutritional supplements for glucose intolerant individuals |
| AU2006249771A1 (en) | 2005-05-24 | 2006-11-30 | Wellgen, Inc. | Compositions and methods for the prevention and treatment of conditions associated with inflammation |
| WO2007094827A2 (en) | 2006-02-10 | 2007-08-23 | Mannatech, Inc. | All natural multivitamin and multimineral dietary supplement formulations for enhanced absorption and biological utilization |
| GB0607402D0 (en) * | 2006-04-12 | 2006-05-24 | Barts & London Nhs Trust | Therapeutic composition and use |
| US8333997B2 (en) * | 2006-06-21 | 2012-12-18 | Albert Einstein College Of Medicine Of Yeshiva University | Compositions for sustained release of nitric oxide, methods of preparing same and uses thereof |
| DK2124638T3 (en) | 2007-02-26 | 2017-03-20 | Heartbeet Ltd | COMPOSITION INCREASING PERFORMANCE AND USING IT |
| CA2678097C (en) * | 2007-02-26 | 2023-03-14 | Jon Lundberg | New use of nitrites and nitrates and compositions containing these |
| WO2008153762A2 (en) | 2007-05-25 | 2008-12-18 | N30 Pharmaceuticals, Llc | S-nitrosothiol formulations and storage systems |
| EP2219657A4 (en) | 2007-11-15 | 2020-01-08 | Louisiana State University | USE OF NITRITE SALTS IN CHRONIC ISCHEMIA |
| WO2009086470A2 (en) | 2007-12-27 | 2009-07-09 | Aires Pharmaceuticals, Inc. | Aerosolized nitrite and nitric oxide - donating compounds and uses thereof |
| WO2010036236A1 (en) | 2008-09-23 | 2010-04-01 | Baker Hughes Incorporated | Anchor assembly |
| US8568793B2 (en) | 2009-02-11 | 2013-10-29 | Hope Medical Enterprises, Inc. | Sodium nitrite-containing pharmaceutical compositions |
| US20120237617A1 (en) | 2009-06-18 | 2012-09-20 | Theravasc Inc. | Use of nitrite salts in treating tissue damage |
| CA2777066C (en) | 2009-10-14 | 2020-02-18 | TheraVasc, LLC | Pharmaceutical formulations of nitrite and uses thereof |
| US20130209584A1 (en) | 2009-10-14 | 2013-08-15 | Theravasc Inc. | Pharmaceutical formulations of nitrite and uses thereof |
| WO2012135623A1 (en) | 2011-03-31 | 2012-10-04 | Theravasc Inc. | Use of nitrites for the treatment of cerebral amyloid angiopathy, age associated dementia, and cognitive decline |
| US20140112983A1 (en) | 2011-04-14 | 2014-04-24 | Theravasc Inc. | Nitrite compositions and uses thereof |
| US9294956B2 (en) | 2011-12-29 | 2016-03-22 | Qualcomm Incorporated | Application-server-assisted preemptive multicast bearer establishment for real-time low-latency applications |
| CA2899602C (en) * | 2013-02-20 | 2024-01-30 | Theravasc Inc. | Pharmaceutical uses of inorganic nitrites |
-
2008
- 2008-11-17 EP EP08849380.4A patent/EP2219657A4/en not_active Withdrawn
- 2008-11-17 US US12/741,436 patent/US9649334B2/en active Active
- 2008-11-17 JP JP2010534267A patent/JP5795165B2/ja active Active
- 2008-11-17 AU AU2008322437A patent/AU2008322437B2/en not_active Ceased
- 2008-11-17 WO PCT/US2008/083830 patent/WO2009065142A2/en not_active Ceased
- 2008-11-17 CN CN200880116483.4A patent/CN101939014B/zh not_active Expired - Fee Related
-
2010
- 2010-05-12 IL IL205720A patent/IL205720A/en active IP Right Grant
-
2014
- 2014-05-08 JP JP2014097072A patent/JP5908527B2/ja not_active Expired - Fee Related
-
2017
- 2017-04-10 US US15/483,187 patent/US10864229B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011503212A5 (https=) | ||
| JP2014139255A5 (https=) | ||
| FI3716979T3 (fi) | 4-pyrimidiinisulfamidijohdannaisen ja SGLT-2-inhibiittorin yhdistelmä endoteliiniin liittyvien sairauksien hoitamiseksi | |
| JP2015526458A5 (https=) | ||
| NZ593754A (en) | Dpp-iv inhibitors for treatment of diabetes in paediatric patients | |
| FI3661514T3 (fi) | Mavakamteeni käytettäväksi hypertrofisen kardiomyopatian hoidossa | |
| RU2001128504A (ru) | Композиции для стимулирования роста | |
| JP2010511715A5 (https=) | ||
| NZ592615A (en) | Method for treating or preventing thrombosis using 150 mg b.i.d. of dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy | |
| MX2009013937A (es) | Nuevo uso de compuestos quimicos farmacologicamente activos conocidos. | |
| NZ592613A (en) | Method for treating or preventing thrombosis using >150 mg to 300 mg b.i.d. of dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy | |
| JP2008534621A5 (https=) | ||
| Sandhu et al. | Atropine aggravates signs and symptoms of Takotsubo cardiomyopathy | |
| Kayrak et al. | Lithium intoxication causing ST segment elevation and wandering atrial rhythms in an elderly patient | |
| Samal et al. | Postoperative analgesia with transdermal diclofenac versus intramuscular diclofenac–a comparative study | |
| Awsakulsutthi et al. | Beraprost sodium for chronic diabetic foot ulcer: a randomized controlled trial in thammasat university hospital | |
| HRP20150936T1 (hr) | Pripravak koristan za sprjeäśavanje dijabetesa tip 2 i njegovih komplikacija kod predijabetiäśnih pacijenata s rezistencijom na inzulin | |
| RU2007117492A (ru) | Применение органических соединений | |
| Yıldırım et al. | Enhanced recovery after surgery (ERAS) protocols in the field of orthopedics and traumatology | |
| RU2599509C1 (ru) | Способ локальной иммунокоррекции при лечении осложненных переломов нижней челюсти | |
| Noor El-Din et al. | Magnesium sulfate versus nitroglycerin in controlled hypotensive anesthesia in middle ear surgeries | |
| Kogelmann et al. | Case study of 8 patients with multiple organ failure treated additionally with CytoSorbents haemadsorption as adjunctive therapy in septic shock and severe SIRS in cardiac failure | |
| JPWO2020166557A5 (https=) | ||
| RU2557882C1 (ru) | Способ проведения премедикации при плановом хирургическом лечении | |
| RU2738831C1 (ru) | Способ консервативного лечения невралгии тройничного нерва |